Bupropion
Generic name: bupropion hydrochloride · Brand names: Wellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin, Zyban (no longer on the market per MedlinePlus)
Quick facts
Drug class
Section
Highlights, Indications and Usage
Source
DailyMed Actavis XL label; MedlinePlus: 'Bupropion is in a class of medications called antidepressants.'
Source text (exact source wording)
Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for:
Rx or otc
Rx (label is a prescribing-information label with a Medication Guide)
Forms and strengths
Section
Highlights, Dosage Forms and Strengths (Actavis XL label; the label lists only the 150 mg tablet)
Source text (exact source wording)
Extended-release tablets: 150 mg (3)
Generic available
Value
Yes: the chosen label is a generic extended-release (XL) label from Actavis Pharma, Inc. (marketing category not shown in the text read)
Source
DailyMed Actavis XL label
Common use one line
Used to treat major depressive disorder and to prevent seasonal affective disorder (XL label).
What it is used for
The XL tablets treat major depressive disorder (MDD) and prevent seasonal major depressive episodes in people with seasonal affective disorder (SAD).
Section
1.1 Major Depressive Disorder (MDD); 1.2 Seasonal Affective Disorder (SAD)
Source text (exact source wording)
Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). Bupropion hydrochloride extended-release tablets (XL) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD).
How it works
MedlinePlus says it works by increasing certain types of activity in the brain.
Medlineplus source text (exact source wording)
It works by increasing certain types of activity in the brain.
Dosage: adults
For MDD the starting dose is 150 mg once daily in the morning, and after 4 days it may be raised to the target dose of 300 mg once daily in the morning. For SAD the starting dose is 150 mg once daily, and after 7 days it may be raised to 300 mg once daily. Swallow the tablets whole; do not crush, divide or chew them. Take in the morning, with or without food.
Section
2.1, 2.2, 2.3
Source text (exact source wording)
2.2 The recommended starting dose for MDD is 150 mg once daily in the morning. After 4 days of dosing, the dose may be increased to the target dose of 300 mg once daily in the morning. 2.3 The recommended starting dose for SAD is 150 mg once daily. After 7 days of dosing, the dose may be increased to the target dose of 300 mg once daily in the morning. Doses above 300 mg of bupropion hydrochloride extended-release were not assessed in the SAD trials. 2.1 Bupropion hydrochloride extended-release tablets (XL) should be swallowed whole and not crushed, divided, or chewed. Bupropion hydrochloride extended-release tablets (XL) should be administered in the morning and may be taken with or without food.
Dosage adjustments
Drug interaction caps
With ritonavir, lopinavir or efavirenz, a higher bupropion dose may be needed but must not exceed the maximum recommended dose.
Section
7.1 Inducers of CYP2B6
Source text (exact source wording)
Dosage increase of bupropion hydrochloride extended-release tablets (XL) may be necessary when coadministered with ritonavir, lopinavir, or efavirenz but should not exceed the maximum recommended dose [see Clinical Pharmacology (12.3)].
Kidney
Consider a lower dose and/or less frequent dosing in people with kidney impairment (glomerular filtration rate less than 90 mL/min).
Section
2.7
Source text (exact source wording)
Consider reducing the dose and/or frequency of bupropion hydrochloride extended-release tablets (XL) in patients with renal impairment (glomerular filtration rate less than 90 mL/min)
Liver
In moderate to severe liver impairment (Child-Pugh score: 7 to 15) the maximum dose is 150 mg every other day. In mild liver impairment (Child-Pugh score: 5 to 6) consider a lower dose and/or less frequent dosing.
Section
2.6
Source text (exact source wording)
In patients with moderate to severe hepatic impairment (Child-Pugh score: 7 to 15), the maximum dose is 150 mg every other day. In patients with mild hepatic impairment (Child-Pugh score: 5 to 6), consider reducing the dose and/or frequency of dosing
Missed dose
MedlinePlus says to skip the missed dose, keep your regular schedule, and not take a double dose.
Medlineplus source text (exact source wording)
Skip the missed dose and continue your regular dosing schedule. Always allow the full scheduled amount of time to pass between doses of bupropion. Do not take a double dose to make up for a missed one.
Overdose
Call poison control at 1-800-222-1222. There are no known antidotes for bupropion. Treatment is supportive care with close medical supervision and monitoring.
MedlinePlus lists seizure, hallucinating, loss of consciousness and rapid or pounding heartbeat as overdose symptoms.
Section
10.2 Overdosage Management
Source text (exact source wording)
Consult a Certified Poison Control Center for up-to-date guidance and advice. Call 1-800-222-1222 or refer to www.poison.org. There are no known antidotes for bupropion. In case of an overdose, provide supportive care, including close medical supervision and monitoring. Consider the possibility of multiple drug overdose.
Medlineplus source text (exact source wording)
Symptoms of overdose may include the following: seizure hallucinating (seeing things or hearing voices that do not exist) loss of consciousness rapid or pounding heartbeat
Storage
Store at 20° to 25°C (68° to 77°F).
Section
16 HOW SUPPLIED/STORAGE AND HANDLING (storage line only; Actavis-specific)
Source text (exact source wording)
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Medlineplus source text (exact source wording)
Store it at room temperature and away from light, excess heat and moisture (not in the bathroom).
Boxed warning
Antidepressants raised the risk of suicidal thoughts and behavior in children, adolescents and young adults in short-term trials. This increase was not shown in people aged 65 and older. In people of all ages, monitor closely for worsening and for new suicidal thoughts and behaviors, and families and caregivers should watch closely and keep in touch with the prescriber.
Section
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
Source text (exact source wording)
SUICIDALITY AND ANTIDEPRESSANT DRUGS. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older [see Warnings and Precautions (5.1)]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1)].
Contraindications
Do not use with a seizure disorder.
Section
4
Source text (exact source wording)
Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder.
Do not use with a current or prior diagnosis of bulimia or anorexia nervosa because seizures were more frequent in these patients.
Section
4
Source text (exact source wording)
Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL)
Do not use while abruptly stopping alcohol, benzodiazepines, barbiturates or antiepileptic drugs.
Section
4
Source text (exact source wording)
Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs
Do not use with MAOIs meant for psychiatric conditions, or within 14 days of stopping one (or within 14 days of stopping bupropion). Do not start bupropion in a patient treated with linezolid or intravenous methylene blue.
Section
4
Source text (exact source wording)
The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) is contraindicated. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated
Do not use if you are known to be allergic to bupropion or the other ingredients.
Section
4
Source text (exact source wording)
Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported
Warnings and precautions
Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents and young adults (ages 18 to 24). All patients should be watched closely, especially in the first few months and at dose changes.
Heading
5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults
Source text (exact source wording)
Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (Selective Serotonin Reuptake Inhibitors [SSRIs] and others) show that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases
The XL tablets are not approved for smoking cessation, though the sustained-release form is. Serious neuropsychiatric events have been reported in people taking bupropion to quit smoking.
Heading
5.2 Neuropsychiatric Adverse Events and Suicide Risk in Smoking Cessation Treatment
Source text (exact source wording)
Bupropion hydrochloride extended-release tablets (XL) are not approved for smoking cessation treatment; however, bupropion HCl sustained-release is approved for this use. Serious neuropsychiatric adverse events have been reported in patients taking bupropion for smoking cessation.
Bupropion can cause seizures, and the risk is dose-related. The dose should not exceed 300 mg once daily. Increase the dose gradually and stop it, without restarting, if a seizure happens.
Heading
5.3 Seizure
Note
The label's Highlights say 'limiting daily dose to 450 mg' while section 5.3 says 'should not exceed 300 mg once daily' and the same section later says 450 mg once daily; recorded as an internal inconsistency in the label.
Source text (exact source wording)
Bupropion hydrochloride extended-release tablets (XL) can cause seizure. The risk of seizure is dose-related. The dose should not exceed 300 mg once daily. Increase the dose gradually. Discontinue bupropion hydrochloride extended-release tablets (XL) and do not restart treatment if the patient experiences a seizure.
Bupropion can raise blood pressure. Blood pressure should be checked before starting and periodically during treatment.
Heading
5.4 Hypertension
Source text (exact source wording)
Treatment with bupropion hydrochloride extended-release tablets (XL) can result in elevated blood pressure and hypertension. Assess blood pressure before initiating treatment with bupropion hydrochloride extended-release tablets (XL), and monitor periodically during treatment.
Antidepressants can trigger manic, mixed or hypomanic episodes. Patients should be screened for bipolar disorder before starting.
Heading
5.5 Activation of Mania/Hypomania
Source text (exact source wording)
Antidepressant treatment can precipitate a manic, mixed, or hypomanic manic episode. Prior to initiating bupropion hydrochloride extended-release tablets (XL), screen patients for a history of bipolar disorder and the presence of risk factors for bipolar disorder
Some patients had delusions, hallucinations, psychosis, concentration problems, paranoia or confusion. Stop the medicine if these occur.
Heading
5.6 Psychosis and Other Neuropsychiatric Reactions
Source text (exact source wording)
Depressed patients treated with bupropion have had a variety of neuropsychiatric signs and symptoms, including delusions, hallucinations, psychosis, concentration disturbance, paranoia, and confusion. Discontinue bupropion hydrochloride extended-release tablets (XL) if these reactions occur.
Pupil widening from bupropion may trigger an angle-closure glaucoma attack in a patient with anatomically narrow angles.
Heading
5.7 Angle-Closure Glaucoma
Source text (exact source wording)
The pupillary dilation that occurs following use of many antidepressant drugs including bupropion hydrochloride extended-release tablets (XL) may trigger an angle-closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.
Stop bupropion and consult a healthcare provider if you get an allergic reaction such as skin rash, itching, hives, chest pain, swelling and shortness of breath.
Heading
5.8 Hypersensitivity Reactions
Source text (exact source wording)
Instruct patients to discontinue bupropion hydrochloride extended-release tablets (XL) and consult a healthcare provider if they develop an allergic or anaphylactoid/anaphylactic reaction (e.g., skin rash, pruritus, hives, chest pain, edema, and shortness of breath) during treatment.
Pregnancy and breastfeeding
Section
8.2 Lactation, Risk Summary
Source text (exact source wording)
Pregnancy (8.1): NOT CAPTURED VERBATIM (section 8.1 was not read). Lactation (8.2 Risk Summary): Data from published literature report the presence of bupropion and its metabolites in human milk (see Data). There are no data on the effects of bupropion or its metabolites on milk production. Limited data from postmarketing reports have not identified a clear association of adverse reactions in the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for bupropion hydrochloride extended-release tablets (XL) and any potential adverse effects on the breastfed child from bupropion hydrochloride extended-release tablets (XL) or from the underlying maternal condition.
Medlineplus source text (exact source wording)
tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking bupropion, call your doctor.
Side effects
Common
The most common reactions (incidence ≥5% and at least twice the placebo rate) are dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency and rash.
Threshold
incidence ≥5%; ≥2× placebo rate
Section
Highlights, Adverse Reactions
Note
These come from sustained-release bupropion trials (300 mg and 400 mg per day), as the label states in 6.1.
Source text (exact source wording)
Most common adverse reactions are (incidence ≥5%; ≥2× placebo rate): dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, rash. (6.1)
Less common
In SAD trials headache was 34% with bupropion versus 26% with placebo, dry mouth 26% versus 15%, insomnia 20% versus 13%, and nausea 13% versus 8%. Constipation was 9% versus 2% and decreased appetite 4% versus 1%.
Section
6.1 Seasonal Affective Disorder, Table 4
Source text (exact source wording)
Table 4 (SAD trials, bupropion extended-release n=537 vs placebo n=511; reactions at an incidence of 2% or more and more frequent than placebo): Dry mouth 26% vs 15%; Nausea 13% vs 8%; Constipation 9% vs 2%; Flatulence 6% vs 3%; Abdominal pain 2% vs <1%; Headache 34% vs 26%; Dizziness 6% vs 5%; Tremor 3% vs <1%; Nasopharyngitis 13% vs 12%; Upper respiratory tract infection 9% vs 8%; Sinusitis 5% vs 4%; Insomnia 20% vs 13%; Anxiety 7% vs 5%; Abnormal dreams 3% vs 2%; Agitation 2% vs <1%; Myalgia 3% vs 2%; Pain in extremity 3% vs 2%; Cough 4% vs 3%; Feeling jittery 3% vs 2%; Rash 3% vs 2%; Decreased appetite 4% vs 1%; Dysmenorrhea 2% vs <1%; Tinnitus 3% vs <1%; Hypertension 2% vs 0%.
Serious
Serious problems include seizures, high blood pressure, mania, psychosis, angle-closure glaucoma and allergic reactions. MedlinePlus says to call your doctor right away for seizures, confusion, hallucinations, irrational fears, a rapid, pounding or irregular heartbeat, or greatly increased energy with severe trouble sleeping and racing thoughts.
Label section
6 ADVERSE REACTIONS; 6.2 Postmarketing Experience
Label source text (exact source wording)
Seizure [see Warnings and Precautions (5.3)]. Hypertension [see Warnings and Precautions (5.4)]. Activation of mania or hypomania [see Warnings and Precautions (5.5)]. Psychosis and other neuropsychiatric events [see Warnings and Precautions (5.6)]. Angle-Closure Glaucoma. Hypersensitivity reactions. Postmarketing (6.2) Skin and Subcutaneous Tissue Disorders: Maculopapular rash, alopecia, angioedema, exfoliative dermatitis, hirsutism, acute generalized exanthematous pustulosis, and drug reaction with eosinophilias and systemic symptoms (DRESS).
Medlineplus source text (exact source wording)
Some side effects can be serious. If you experience any of the following symptoms or those listed in the IMPORTANT WARNING or SPECIAL PRECAUTIONS sections, call your doctor immediately or get emergency medical treatment: seizures confusion, hallucinating (seeing things or hearing voices that do not exist).irrational fears rapid, pounding, or irregular heartbeat greatly increased energy, severe trouble sleeping, racing thoughts, reckless behavior, unusually grand ideas, excessive happiness or irritability, talking more or faster than usual
Led to discontinuation
In SAD trials 9% of patients on bupropion XL and 5% on placebo stopped because of side effects, most often insomnia (2% vs. <1%) and headache (1% vs. <1%).
Section
6.1 Seasonal Affective Disorder
Source text (exact source wording)
In placebo-controlled clinical trials in SAD, 9% of patients treated with bupropion hydrochloride extended-release tablets (XL) and 5% of patients treated with placebo discontinued treatment because of adverse reactions. The adverse reactions leading to discontinuation in at least 1% of patients treated with bupropion and at a rate numerically greater than the placebo rate were insomnia (2% vs. <1%) and headache (1% vs. <1%).
Interactions
Drugs
At least 14 days should pass between stopping an MAOI and starting bupropion, and between stopping bupropion and starting an MAOI antidepressant.
Name
MAO inhibitors, linezolid, intravenous methylene blue
Section
4; 2.8; 2.9
Source text (exact source wording)
At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with bupropion hydrochloride extended-release tablets (XL). Conversely, at least 14 days should be allowed after stopping bupropion hydrochloride extended-release tablets (XL) before starting an MAOI antidepressant.
Ritonavir, lopinavir and efavirenz can lower bupropion levels, so a higher dose may be needed but not above the maximum. Carbamazepine, phenobarbital and phenytoin may also lower bupropion exposure.
Name
CYP2B6 inducers (ritonavir, lopinavir, efavirenz, carbamazepine, phenobarbital, phenytoin)
Section
7.1
Source text (exact source wording)
Ritonavir, Lopinavir, and Efavirenz: Concomitant treatment with these drugs can decrease bupropion and hydroxybupropion exposure. Dosage increase of bupropion hydrochloride extended-release tablets (XL) may be necessary when coadministered with ritonavir, lopinavir, or efavirenz but should not exceed the maximum recommended dose
Ticlopidine and clopidogrel can increase bupropion exposure, so the dose may need adjusting.
Name
CYP2B6 inhibitors (ticlopidine, clopidogrel)
Section
7.1
Source text (exact source wording)
Ticlopidine and Clopidogrel: Concomitant treatment with these drugs can increase bupropion exposures but decrease hydroxybupropion exposure.
Bupropion can raise levels of certain antidepressants, antipsychotics, beta-blockers and Type 1C antiarrhythmics, so those doses may need to be lowered.
Name
Drugs metabolized by CYP2D6
Section
7.2
Source text (exact source wording)
Such drugs include certain antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g., haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, and flecainide). When used concomitantly with bupropion hydrochloride extended-release tablets (XL), it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.
Use extreme caution with other drugs that lower the seizure threshold.
Name
Drugs that lower seizure threshold
Section
7.3
Source text (exact source wording)
Use extreme caution when coadministering bupropion hydrochloride extended-release tablets (XL) with other drugs that lower the seizure threshold (e.g., other bupropion products, antipsychotics, antidepressants, theophylline, or systemic corticosteroids).
Nervous system toxicity has been reported with levodopa or amantadine, so use caution.
Name
Levodopa and amantadine
Section
7.4
Source text (exact source wording)
CNS toxicity has been reported when bupropion was coadministered with levodopa or amantadine. Use caution when administering bupropion hydrochloride extended-release tablets (XL) concomitantly with these drugs.
Bupropion can cause false-positive urine test results for amphetamines.
Name
Drug-laboratory test (amphetamine urine tests)
Section
Highlights, 7.7
Source text (exact source wording)
Drug-laboratory test interactions: Bupropion hydrochloride extended-release tablets (XL) can cause false-positive urine test results for amphetamines. (7.7)
Food and alcohol
Alcohol use during treatment should be minimized or avoided.
Name
Alcohol
Section
7.5 Use with Alcohol
Source text (exact source wording)
The consumption of alcohol during treatment with bupropion hydrochloride extended-release tablets (XL) should be minimized or avoided.
The XL tablets may be taken with or without food.
Name
Food
Section
2.1
Source text (exact source wording)
may be taken with or without food.
Patient tips
Swallow extended-release tablets whole. It may take 4 weeks or longer to feel the full benefit. Keep taking it even if you feel well and do not stop without talking to your doctor. Avoid taking it too close to bedtime if you have trouble sleeping. You may see an empty tablet shell in your stool; that does not mean you missed your dose. Call your doctor right away for worsening depression, suicidal thoughts, or unusual changes in behavior.
Source
MedlinePlus https://medlineplus.gov/druginfo/meds/a695033.html
Label source text (exact source wording)
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Medlineplus source text (exact source wording)
Swallow the sustained-release and extended-release tablets whole; do not split, chew, or crush them. It may take 4 weeks or longer before you feel the full benefit of bupropion. Continue to take bupropion even if you feel well. Do not stop taking bupropion without talking to your doctor. If you have trouble falling asleep or staying asleep, do not take bupropion too close to bedtime. If you are taking the extended-release tablet, you may notice something that looks like a tablet in your stool. This is just the empty tablet shell and does not mean that you did not get your complete dose of medication.
Alternatives
Class
aminoketone antidepressant (label wording); antidepressant (MedlinePlus)
Class source
DailyMed Actavis XL label Highlights; MedlinePlus
Note
No recommendation made. Alternatives depend on indication and form.
Frequently asked questions
Question
What is bupropion XL used for?
Answer
The XL tablets treat major depressive disorder (MDD) and prevent seasonal major depressive episodes in people with seasonal affective disorder (SAD).
Source section
1 INDICATIONS AND USAGE
Source
DailyMed Actavis XL label
Question
When and how should I take it?
Answer
Take it once daily in the morning, with or without food. Swallow the tablet whole and do not crush, divide or chew it.
Source section
2.1 General Instructions for Use
Source
DailyMed Actavis XL label
Question
What is the usual dose?
Answer
The starting dose for MDD is 150 mg once daily in the morning. After 4 days it may be increased to 300 mg once daily. Your own dose comes from your prescriber.
Source section
2.2
Source
DailyMed Actavis XL label
Question
Can I drink alcohol with bupropion?
Answer
Alcohol use during treatment should be minimized or avoided.
Source section
7.5 Use with Alcohol
Source
DailyMed Actavis XL label
Question
What are the most common side effects?
Answer
The most common reactions (incidence ≥5% and at least twice the placebo rate) include dry mouth, nausea, insomnia, dizziness, agitation, anxiety, tremor, sweating, tinnitus and rash.
Source section
Highlights, Adverse Reactions
Source
DailyMed Actavis XL label
Question
What if I miss a dose?
Answer
MedlinePlus says to skip the missed dose, continue the regular schedule, and not take a double dose.
Source section
What should I do if I forget a dose?
Source
MedlinePlus
Question
Does bupropion raise seizure risk?
Answer
Yes. The risk of seizure is dose-related, and the label says to increase the dose gradually. It is contraindicated in people with a seizure disorder.
Source section
5.3 Seizure; 4 CONTRAINDICATIONS
Source
DailyMed Actavis XL label
Question
Should I stop bupropion when I feel better?
Answer
No. MedlinePlus says to keep taking it even if you feel well and not stop without talking to your doctor.
Source section
How should this medicine be used?
Source
MedlinePlus
Sources
- DailyMed bupropion hydrochloride XL tablets, Actavis Pharma, Inc. (chosen)
Set id: a1e768fd-c28f-4b49-822d-ccc315b4099c · Label effective or revised date: Revised: 7/2026 · Dailymed version date: DailyMed published date Oct 12, 2026 (from spls.json list) · Fetched at: 2026-11-02 · Sections used: Highlights, 1, 2, 3, 4, 5, 6, 7.1-7.5 (text capped at 50,000 of 113,654 characters; 7.6 on, 8.1, 8.4-8.7, 9, 12 not read; 8.2, 10.2 and 16 storage line read by short slices) - MedlinePlus Bupropion
Label effective or revised date: Last Revised - 11/15/2025 · Fetched at: 2026-11-02 - DailyMed list API
Fetched at: 2026-11-02
Information is taken from the cited sources and is for general reference only. It is not medical advice. Report side effects to FDA MedWatch at 1-800-FDA-1088. For a poison emergency call 1-800-222-1222. See prices for this drug